Skip to main content
. Author manuscript; available in PMC: 2020 Jan 15.
Published in final edited form as: Clin Cancer Res. 2019 Apr 16;25(14):4231–4237. doi: 10.1158/1078-0432.CCR-18-3886

Table 4.

Response rates by molecular subgroup

Molecular Mutations Number of responding patients with mutation/ number of total patients with mutations (%)
FLT3 ITD 4/7 (57%)
TET2 2/2 (100%)
JAK3 1/1 (100%)
ASXL1 3/3 (100%)
LUC7 1/ 2 (50%)
TP53 1/ 2 (50%)
CKIT 0/1 (0%)
SRSF2 2/2 (100%)
IDH2 1/1 (100%)
STAG2 1/1 (100%)
NPM1 1/ 4 (25%)
DNMT3 3/3 (100%)
WT1 0/1 (0%)
SMC1a 0/1 (0%)
BCORL1 0/ 1 (0%)
IDH1 2/2 (100%)
STAT3 1/1 (100%)